Enliven reports 2023 net loss $71.6M; cash $253M; ELVN-001 data due Q2 2024

Enliven Therapeutics, Inc.

Net loss of $71.6M for full year 2023, up from $37.7M in 2022; R&D spend $64.6M.
Cash, cash equivalents and marketable securities $253.1M; expected runway into early 2026.
Phase 1a ELVN-001 proof-of-concept data expected Q2 2024 (n>20 patients at efficacious dose).
ELVN-002 IND cleared for combination with trastuzumab in HER2+ cancers; first patient dosing by mid-2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Enliven Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income net loss of $19.4 million for the fourth quarter of 2023.

Period: the fourth quarter and full year ended December 31, 2023
Net income: net loss of $19.4 million for the fourth quarter of 2023
Result: reported results

Exact text from the filing

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today reported financial results for the fourth quarter and full year ended December 31, 2023

View on SEC.gov

Browse all earnings releases →

Enliven Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-031482

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.